Claims for Patent: 10,941,118

Summary for Patent: 10,941,118

Title:	Solid state forms of (S)-2-(((S)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl)amino)-N-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1H-imidazol-4-yl)pentanamide and uses thereof
Abstract:	The present disclosure relates to: a) solid state forms of hydrobromide salts of Compound 1; b) pharmaceutical compositions comprising one or more solid state forms of hydrobromide salts of Compound 1, and, optionally, a pharmaceutically acceptable carrier; c) methods of treating tumors or cancers by administering one or more solid state forms of hydrobromide salts of Compound 1 to a subject in need thereof; and d) methods for the preparation of solid state forms of Compound 1.
Inventor(s):	Elaine Greer, Stephen Anderson, Mark Maloney, Shu Yu, Ekaterina Albert, Emily Rigsbee
Assignee:	Pfizer Corp SRL
Application Number:	US16/886,622
Patent Claims:	1. A crystalline form of a hydrobromide salt of (S)-2-(((S)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl)amino)-N-(1-(2-methyl-1-(neopentylamino) propan-2-yl)-1H-imidazol -4-yl)pentanamide of Formula (I) selected from the group consisting of: a) crystalline Form A, wherein Form A is characterized by an XRPD pattern having peaks at 8.8±0.2, 9.8±0.2, and 23.3±0.2 degrees two theta; b) crystalline Form B, wherein Form B is characterized by an XRPD pattern substantially as shown in FIG. 4; c) crystalline Form D, wherein Form D is characterized by an XRPD pattern substantially as shown in FIG. 11; d) crystalline Form E, wherein Form E is characterized by an XRPD pattern substantially as shown in FIG. 14; e) crystalline Form F, wherein Form F is characterized by an XRPD pattern substantially as shown in FIG. 17; f) crystalline Form F′, wherein Form F′ is characterized by an XRPD pattern substantially as shown in FIG. 18; g) crystalline Form G, wherein Form G is characterized by an XRPD pattern substantially as shown in FIG. 21; h) crystalline Form H, wherein Form H is characterized by an XRPD pattern substantially as shown in FIG. 22; i) crystalline Form H′, wherein Form H′ is characterized by an XRPD pattern substantially as shown in FIG. 23; j) crystalline Form J, wherein Form J is characterized by an XRPD pattern substantially as shown in FIG. 24; k) crystalline Form K, wherein Form K is characterized by an XRPD pattern substantially as shown in FIG. 25; 1) crystalline Form L, wherein Form L is characterized by an XRPD pattern substantially as shown in FIG. 26; m) crystalline Form M, wherein Form M is characterized by an XRPD pattern substantially as shown in FIG. 29; and n) crystalline Form N, wherein Form N is characterized by an XRPD pattern substantially as shown in FIG. 30. 2. The crystalline form of claim 1, wherein the crystalline form is crystalline Form B, wherein Form B is characterized by an XRPD pattern substantially as shown in FIG. 4. 3. The crystalline form of claim 1, wherein the crystalline form is crystalline Form D, wherein Form D is characterized by an XRPD pattern substantially as shown in FIG. 11. 4. The crystalline form of claim 1, wherein the crystalline form is Form E, wherein Form E is characterized by an XRPD pattern substantially as shown in FIG. 14. 5. The crystalline form of claim 1, wherein the crystalline form is Form F, wherein Form F is characterized by an XRPD pattern substantially as shown in FIG. 17. 6. The crystalline form of claim 1, wherein the crystalline form is Form F′, wherein Form F′ is characterized by an XRPD pattern substantially as shown in FIG. 18. 7. The crystalline form of claim 1, wherein the crystalline form is Form G, wherein Form G is characterized by an XRPD pattern substantially as shown in FIG. 21. 8. The crystalline form of claim 1, wherein the crystalline form is Form H, wherein Form H is characterized by an XRPD pattern substantially as shown in FIG. 22. 9. The crystalline form of claim 1, wherein the crystalline form is Form H′, wherein Form H′ is characterized by an XRPD pattern substantially as shown in FIG. 23. 10. The crystalline form of claim 1, wherein the crystalline form is Form J, wherein Form J is characterized by an XRPD pattern substantially as shown in FIG. 24. 11. The crystalline form of claim 1, wherein the crystalline form is Form K, wherein Form K is characterized by an XRPD pattern substantially as shown in FIG. 25. 12. The crystalline form of claim 1, wherein the crystalline form is Form L, wherein Form L is characterized by an XRPD pattern substantially as shown in FIG. 26. 13. The crystalline form of claim 1, wherein the crystalline form is Form M, wherein Form M is characterized by an XRPD pattern substantially as shown in FIG. 29. 14. The crystalline form of claim 1, wherein the crystalline form is Form N, wherein Form N is characterized by an XRPD pattern substantially as shown in FIG. 30. 15. A composition comprising a crystalline form of claim 1, wherein the crystalline form has one or more of a D[V,0.10] particle size between 0.5 μm and 15 μm, a D[V,0.50] particle size between 2 μm and 30 μm, a D[V,0.90] particle size between 8 μm and 600 μm, or a D[4,3] particle size of 5 μm to 200 μm. 16. A pharmaceutical composition comprising a crystalline form or composition of claim 1 and a pharmaceutically acceptable carrier. 17. The pharmaceutical composition of claim 16, wherein the pharmaceutical composition is a tablet. 18. The pharmaceutical composition of claim 16, wherein the pharmaceutical composition comprises 25 mg to 400 mg of the hydrobromide salt of (S)-2-(((S)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl)amino)-N-(1-(2-methyl -1-(neopentylamino) propan-2-yl)-1H-imidazol-4-yl)pentanamide. 19. The pharmaceutical composition of claim 16, wherein the pharmaceutical composition comprises 50 mg of the hydrobromide salt of (S)-2-(((S)-6, 8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl)amino)-N-(1-(2-methyl-1-(neopentylamino) propan-2-y1)-1H-imidazol-4-yl)pentanamide. 20. The pharmaceutical composition of claim 16, wherein the pharmaceutical composition comprises 100 mg of the hydrobromide salt of (S)-2-(((S)-6, 8-difluoro-1,2,3 ,4-tetrahydronaphthalen-2-yl)amino)-N-(1-(2-methyl-1-(neopentylamino) propan-2-y1)-1Himidazol-4-yl)pentanamide. 21. A method of treating desmoid tumors comprising administering to a subject in need of such treatment a pharmaceutical composition of claim 16. 22. The method of claim 21, wherein the subject is administered 50 mg to 500 mg of the hydrobromide salt of (S)-2-(((S)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl)amino)-N-(1-(2-methyl-1-(neopentylamino) propan-2-yl)-1H-imidazol -4-yl)pentanamide daily. 23. The method of claim 21, wherein the subject is administered 100 mg to 400 mg of the hydrobromide salt of (S)-2-(((S)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl)amino)-N-(1-(2-methyl-1-(neopentylamino) propan-2-yl)-1H-imidazol -4-yl)pentanamide daily. 24. The method of claim 21, wherein the subject is administered 300 mg of the hydrobromide salt of (S)-2-(((S)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl)amino)-N-(1-(2-methyl-1-(neopentylamino) propan-2-yl)-1H-imidazol-4-yl)pentanamide daily. 25. The method of claim 21, wherein the subject is administered 200 mg of the hydrobromide salt of (S)-2-(((S)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl)amino)-N-(1-(2-methyl-1-(neopentylamino) propan-2-yl)-1H-imidazol-4-yl)pentanamide daily. 26. The method of claim 21, wherein the subject is administered a total daily dose provided as two separate doses. 27. The method of claim 26, wherein the total daily dose is provided as two separate doses of 150 mg. 28. The method of claim 26, wherein the total daily dose is provided as two separate doses of 100 mg.